Empowered Patient Podcast

David Johnson, CEO and co-founder, GigaGen discusses the company's recombinant intravenous immunoglobulin (IVIG) therapy in development to treat patients with primary immune deficiencies and its potential to overcome limitations of current IVIG plasma-based therapies.  David describes how GigaGen's recombinant IVIG is not tied to plasma supplies and has the potential to provide a high purity, consistent and ultimately safer treatment alternative for patients in need. #primaryimmunedeficiency #IVIG #antibody #PolyclonalAntibodies @GigaGeninc GigaGen.com Download the entire transcript here Page 1 of the Interview with David Johnson GigaGen Karen Jagoda: Welcome to the EmpoweredPatientPodcast.com show. I'm Karen Jagoda, and my guest today is David Johnson. He's the CEO and co-founder of GigaGen, that's G-I-G-A G-E-N.com. And Dave is an inventor, he's an entrepreneur and is an expert in single cell immunology. And we're talking today about IVIG therapies for patients with primary immune deficiencies. And Dave, I